AVEO Pharmaceuticals - Stock Price History | AVEO

Historical daily share price chart and data for AVEO Pharmaceuticals since 2021 adjusted for splits. The latest closing stock price for AVEO Pharmaceuticals as of October 22, 2021 is 6.66.
  • The all-time high AVEO Pharmaceuticals stock closing price was 207.70 on July 21, 2011.
  • The AVEO Pharmaceuticals 52-week high stock price is 18.24, which is 173.9% above the current share price.
  • The AVEO Pharmaceuticals 52-week low stock price is 4.95, which is 25.7% below the current share price.
  • The average AVEO Pharmaceuticals stock price for the last 52 weeks is 6.80.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
AVEO Pharmaceuticals Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 5.4878 6.3230 9.9900 2.6000 5.7700 -7.58%
2019 8.3998 18.3000 21.2000 5.1000 6.2430 -60.98%
2018 25.1285 27.4000 34.8000 14.9000 16.0000 -42.65%
2017 19.3154 6.0330 39.9000 5.7000 27.9000 416.67%
2016 8.9026 12.6000 12.6000 5.4000 5.4000 -57.14%
2015 13.8324 8.8000 24.9000 8.0000 12.6000 49.96%
2014 13.1489 18.0000 20.1000 6.5000 8.4020 -54.09%
2013 39.7181 80.7750 87.4000 16.1000 18.3000 -77.27%
2012 108.8962 138.3000 149.7000 59.7000 80.5000 -53.20%
2011 161.9282 148.7000 207.7000 130.6000 172.0000 17.65%
2010 102.7713 89.9000 174.1000 61.0500 146.2000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.227B $0.006B
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company's next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57